Phase 2 Trial of Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma(PCNSL), and Other Extra-Nodal Diffuse Large B-cell Lymphomas
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 16 Oct 2017
At a glance
- Drugs Pembrolizumab (Primary)
- Indications B cell lymphoma; Cutaneous B-cell lymphoma; Diffuse large B cell lymphoma
- Focus Therapeutic Use
- 10 Oct 2017 Planned initiation date changed from 13 Oct 2017 to 18 Oct 2017.
- 07 Oct 2017 Planned initiation date changed from 3 Oct 2017 to 13 Oct 2017.
- 28 Sep 2017 Planned initiation date changed from 29 Sep 2017 to 3 Oct 2017.